GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...
March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...
For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a ...
The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...
Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly ...
The diabetes drugs, which usually cost about $525, are listed on TrumpRx starting around $55. The COPD inhaler drops from about $276 to $35, according to the White House. “Those are pretty significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results